Back to news

Why Vertex Pharmaceuticals (VRTX) Stock Is Down Today

Investivoq PriceTracker

Vertex Pharmaceuticals (VRTX) is down 3.9% today. Here is some analysis on what might have caused this price movement. ([stockanalysis.com](https://stockanalysis.com/stocks/vrtx/history/))

Analysis: The most likely explanation is that this is a sentiment-driven pullback rather than a reaction to a new company-specific negative event. Vertex had no fresh material filing or major new announcement on October 13, while the broader biotech group was weaker, which suggests sector pressure and profit-taking may be driving the move. ([investors.vrtx.com](https://investors.vrtx.com/news-events/press-releases))

Details:

  • VRTX was trading at about $487.21, down 3.90%, in the afternoon on October 13, 2026. ([stockanalysis.com](https://stockanalysis.com/stocks/vrtx/history/))
  • The Nasdaq Biotechnology Index was down 1.84% on October 13, showing that biotech shares were under pressure more broadly. ([indexes.nasdaqomx.com](https://indexes.nasdaqomx.com/Index/Overview/NBI?mod=article_inline))
  • Vertex’s investor site shows its most recent press release was on October 9 about new ALYFTREK data, and another on October 7 set November 2, 2026 as the date for third-quarter results. ([investors.vrtx.com](https://investors.vrtx.com/news-events/press-releases?utm_source=openai))
  • The company’s filings page shows no new October 13 SEC filing, with the latest listed items being September 10 insider ownership forms and a September 1 current report. ([investors.vrtx.com](https://investors.vrtx.com/financial-information/sec-filings?field_nir_sec_cik_target_id=&field_nir_sec_date_filed_value=&items_per_page=10&items_per_page_toggle=0&mobile=1&order=field_nir_sec_description&page=339&sort=asc))

    • Sources:

    Vertex Pharmaceuticals, SEC, Nasdaq, Stock Analysis

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $VRTX Insider Trading Activity

    VRTX Insider Trades

    $VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

    Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:

    • CARMEN BOZIC (EVP and CMO) has made 0 purchases and 5 sales selling 14,411 shares for an estimated $6,516,733.
    • JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 3 sales selling 2,760 shares for an estimated $1,249,711.
    • DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) sold 1,541 shares for an estimated $799,779
    • OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for an estimated $787,485
    • SANGEETA N. BHATIA sold 318 shares for an estimated $134,746

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive VRTX Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $VRTX Hedge Fund Activity

    We have seen 855 institutional investors add shares of $VRTX stock to their portfolio, and 713 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 6,517,600 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,237,487,448
    • INVESCO LTD. added 5,481,995 shares (+214.1%) to their portfolio in Q2 2026, for an estimated $2,723,071,376
    • FRANKLIN RESOURCES INC added 2,796,121 shares (+507.3%) to their portfolio in Q2 2026, for an estimated $1,388,917,184
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,041,282 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,013,966,007
    • CAPITAL RESEARCH GLOBAL INVESTORS removed 1,635,327 shares (-7.7%) from their portfolio in Q2 2026, for an estimated $812,315,980
    • VICTORY CAPITAL MANAGEMENT INC removed 1,183,614 shares (-35.3%) from their portfolio in Q2 2026, for an estimated $587,936,582
    • ALLIANCEBERNSTEIN L.P. removed 891,471 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $442,820,389

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $VRTX Congressional Stock Trading

    Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:

    • REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 08/26.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $VRTX Price Targets

    Multiple analysts have issued price targets for $VRTX recently. We have seen 6 analysts offer price targets for $VRTX in the last 6 months, with a median target of $571.0.

    Here are some recent targets:

    • Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
    • Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
    • Eliana Merle from Barclays set a target price of $615.0 on 05/06/2026
    • Terence Flynn from Morgan Stanley set a target price of $616.0 on 05/05/2026
    • William Pickering from Bernstein set a target price of $572.0 on 05/05/2026
    • Whitney Ijem from Canaccord Genuity set a target price of $436.0 on 05/05/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.